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Although thyroid eye disease is a common complication of Graves’ disease, the pathogene-
sis of the orbital disease is poorly understood. Most authorities implicate the immune
response as an important causal factor. We sought to clarify pathogenesis by using gene
expression microarray.
Methods
An international consortium of ocular pathologists and orbital surgeons contributed formalin
fixed orbital biopsies. RNA was extracted from orbital tissue from 20 healthy controls, 25
patients with thyroid eye disease (TED), 25 patients with nonspecific orbital inflammation
(NSOI), 7 patients with sarcoidosis and 6 patients with granulomatosis with polyangiitis
(GPA). Tissue was divided into a discovery set and a validation set. Gene expression was
quantified using Affymetrix U133 Plus 2.0 microarrays which include 54,000 probe sets.
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Results
Principal component analysis showed that gene expression from tissue from patients with
TED more closely resembled gene expression from healthy control tissue in comparison to
gene expression characteristic of sarcoidosis, NSOI, or granulomatosis with polyangiitis.
Unsupervised cluster dendrograms further indicated the similarity between TED and
healthy controls. Heat maps based on gene expression for cytokines, chemokines, or their
receptors showed that these inflammatory markers were associated with NSOI, sarcoido-
sis, or GPAmuch more frequently than with TED.
Conclusion
This is the first study to compare gene expression in TED to gene expression associated
with other causes of exophthalmos. The juxtaposition shows that inflammatory markers are
far less characteristic of TED relative to other orbital inflammatory diseases.
Introduction
The rationale to classify Graves’ disease as an autoimmune disease is irrefutable. Graves’ dis-
ease is characterized by an autoantibody to the thyroid stimulating hormone receptor. The bio-
logical activity of this autoantibody results in hyperthyroidism.
It is also widely believed that thyroid eye disease (TED) is autoimmune. First, it frequently
coexists with Graves’ disease, so there is “guilt by association”. Many patients with Graves’,
however, do not develop TED, nor is it clear that the autoantibody responsible for hyperthy-
roidism plays a pathogenic role in orbital disease. Thyroid eye disease is associated with poly-
morphisms in HLA molecules [1] and polymorphisms in receptors that modulate the immune
response [2]. An increase in cytokine mRNA expression has been noted in orbital tissue from
patients with TED [3]. Cells like fibroblasts or myocytes cultured from the orbit affected by
TED display an increase in cytokine synthesis [4, 5]. Elevated levels of circulating cytokines
have been detected in patients with TED [6, 7]. Patients with TED have an increased risk for
gastrointestinal autoimmunity [8]. Furthermore, many of the strategies aimed at the treatment
of TED are based on immunosuppression [9, 10].
In order to clarify the pathogenesis of TED, we have organized a consortium of international
centers. We have employed gene expression microarray to analyze the detection of transcripts
in orbital tissue from patients with thyroid eye disease. While this type of analysis has been
reported previously [11–15], ours is the first report to compare gene expression among differ-
ent forms of orbital inflammation. By juxtaposing gene expression in TED relative to other
causes of orbital inflammation, we find a surprisingly limited immune-response signature rela-
tive to several other causes of orbital inflammation.
Materials and Methods
Centers and IRB approval
This study was approved by the Institutional Review Board (IRB) at Oregon Health & Science
University and at each of the other contributing centers: Columbia University IRB, University
of California San Diego IRB, Wake Forest University IRB, Medical College of Wisconsin IRB,
Mount Carmel (Ohio) IRB, University of Miami IRB, University of British Columbia Clinical
Immune Response in Thyroid Eye Disease
PLOS ONE | DOI:10.1371/journal.pone.0137654 September 15, 2015 2 / 12
OHSU), the Stan and Madelle Rosenfeld Family Trust
(JTR), the William and Mary Bauman Foundation
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Research Ethics Board, Royal Adelaide Hospital Research Ethics Committee, King Khaled Eye
Specialist Hospital Human Ethics Committee/Institutional Review Board. Tissue acquisition
was in compliance with the requirements of the local review board including acquisition of
written informed consent from the donor where required. All data were anonymized and de-
identified prior to analysis. The research adhered to the tenets of the Declaration of Helsinki.
Formalin-fixed, paraffin-embedded (FFPE) samples and relevant demographic and clinical
data were obtained. The diagnoses of sarcoidosis, granulomatosis with polyangiitis (GPA) (pre-
viously known as Wegener’s granulomatosis), TED, nonspecific orbital inflammation (NSOI)
(previously also known as orbital pseudotumor or idiopathic orbital inflammation), and nor-
mal were based on the clinical and histopathological information obtained and submitted by
orbital disease specialists and ocular pathologists from their respective institutions. All biopsies
were further reviewed by two of the authors (DJW and HEG) as noted below.
This is a multicenter, international study on previously biopsied orbital tissue. Biopsies of
orbital adipose tissue from a total of 83 subjects were studied (20 controls with no known
orbital disease, 6 with GPA, 7 with sarcoidosis, 25 with TED, and 25 with NSOI). The ages are
summarized in Table 1. The gender distribution was roughly comparable among the 5 groups.
Seventy-six per cent of the TED patients were female, compared to 64% of those with NSOI,
83% of those with sarcoidosis, 67% of those with GPA, and 70% of the healthy controls. Of the
25 patients with TED, 15 were biopsied prior to starting therapy, four had received prior corti-
costeroid therapy, and one had received local radiation. Prior therapy information was not pro-
vided on 5 patients. Nineteen of the 25 patients were known to be hyperthyroid, one was
hypothyroid, and 3 were euthyroid. Thyroid status was not provided on two subjects. Twenty
of the patients had orbital surgery for symptomatic relief. The reason for surgery was not stated
in 5 subjects. Thyroid antibody status was reported in 5 patients and was positive in 3 of these.
The control tissue was obtained during surgery such as blepharoplasty and enucleation on eyes
with non-inflamed orbits.
Pathology Review
Hematoxylin and eosin stained slides of all samples were evaluated in a masked fashion by two
ocular pathologists (D.J.W. and H.E.G.) for histopathological characteristics. The diagnosis
from the pathologists was compared to the diagnosis from the institution where tissue had
been obtained. In some cases, additional stains were requested or additional clinical informa-
tion was reviewed. A few cases with an ambiguous diagnosis were excluded. In all cases
included in this study, a consensus diagnosis was obtained by Drs. Wilson and Rosenbaum,
and the contributing center’s diagnosis was accepted.
Table 1. Ages for each experimental group.
Set 1 Set 2
Diagnosis N Mean age at biopsy N Mean age at biopsy
NSOI 14 44.0 ± 21.8 11 58.5 ± 24.1
Sarcoid 1 60.6 7* 48.8 ± 14.7
TED 14 54.0 ± 14.7 11 48.6 ± 13.0
GPA 4 43.4 ± 14.3 4** 40.0 ± 13.9
Normal 14 61.0 ± 15.6 6 69.7 ± 9.8
*one repeated from set 1;
**two repeated from set 1
doi:10.1371/journal.pone.0137654.t001
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Tissue Preparation and Gene Expression Profiling
RNA extraction and microarray assays were performed in the OHSU Gene Profiling Shared
Resource as previously reported [16]. We used Human U133 Plus 2.0 arrays that contain over
54,000 probe sets for 47,000 human transcripts and variants.
Statistical Analysis
Affymetrix CEL files were normalized by the Robust Multiarray Analysis [17]. Testing for
potential differences in gene expression across disease groups was done by fitting linear models
after controlling for sex and age at biopsy. Mean differences were considered statistically signif-
icant when there was at least 1.5-fold change with a false discovery rate adjusted p-value less
than 0.05. The ‘affy’, ‘caret’ ‘MASS’, ‘limma’ and ‘randomForest’ packages in the R project
(http://www.r-project.org) were used for statistical computations.
Principal component analysis (PCA) was used for two dimensional or three-dimensional
visualization of the dissimilarity in gene expression profiles across the disease groups [18]. A
dendrogram that could be aligned with heat maps was created by unsupervised, hierarchical
cluster analysis. The data used for the PCA plots and dendrogram were restricted to those
probe sets that had significantly different signals for TED, sarcoidosis, GPA, or NSOI groups
compared to normal controls. The GSEA program [19, 20] provided a means to identify
expression differences in predetermined sets of genes without reliance on the FDR p-values
and fold-differences used to select the probe sets employed in the creation of the dendrograms.
The data used for the generation of the heat maps were restricted to 40,450 probe sets with ade-
quate annotation and custom gene lists for immunoglobulins, cytokines, cytokine receptors,
chemokines, and chemokine receptors.
Results
Table 1 shows the mean ages for control groups and for subjects with TED in this study.
Because studies based on multiple statistical comparisons are fraught with “significant” find-
ings that merely represent chance occurrences from multiple statistical tests, we divided our
subjects into a discovery and a validation set. The validation set determines if the differences
found in the discovery set are reproducible.
Fig 1 shows principal component analysis (PCA) plots that compare the difference in gene
expression from TED patients and from healthy controls. In a PCA, the distance between two
Fig 1. Principal component analysis based on significantly up-regulated and significantly down-
regulated probe sets in TED orbital adipose (T) against uninflamed controls (C). The discovery set (Set
1) had 36 significantly up-regulated and 254 significantly down-regulated probe sets. The validation set (Set
2) had 66 significantly up-regulated and 604 significantly down-regulated probe sets. At least 1.5-fold change
with FDR adjusted p-value < 0.05 is considered statistically significant.
doi:10.1371/journal.pone.0137654.g001
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points reflects their relative similarity or dissimilarity. For the discovery set (set 1), the separa-
tion between the two groups indicates that there are clear differences between TED and con-
trols. For the validation set (set 2), there is again a grouping of TED distinct from the controls.
However, only a minority of the probe sets that distinguished TED from controls in the discov-
ery set were reproduced in the validation set. In fact, no probe sets indicated transcripts with a
significantly higher signal (>1.5-fold increase with a false discovery rate adjusted p value of
<0.05) in both the discovery set and the validation set in a comparison between TED and the
healthy controls. Table 2 lists the 29 probe sets (~23 genes) that had significantly lower signals
in tissue from patients with thyroid eye disease compared to tissue from non-diseased controls.
Thus, TED is distinct from controls, but the distinction is not strong.
The PCA plots in Fig 2 compare gene expression in orbital tissue from patients with TED to
orbital tissue from patients with sarcoidosis, NSOI, or GPA. Also included are subjects with no
Table 2. Probe sets with a significantly lower signal in orbital tissue from TED subjects compared to uninflamed controls.
Set 1 Set 2








203305_at F13A1 coagulation factor XIII, A1 polypeptide -3.87 0.012 -3.10 0.019
213800_at CFH complement factor H -3.52 0.022 -3.05 0.002
207277_at CD209 CD209 molecule -4.25 0.006 -2.24 0.027
203407_at PPL periplakin -2.69 0.025 -3.46 0.009
209348_s_at MAF v-maf musculoaponeurotic fibrosarcoma oncogene homolog
(avian)
-3.56 0.046 -2.54 0.040
201212_at LGMN legumain -3.62 0.007 -2.38 0.005
215039_at LOC339524 uncharacterized LOC339524 -3.75 0.011 -2.16 0.024
237351_at LOC100652994 uncharacterized LOC100652994 -3.73 0.000 -2.03 0.028
215870_s_at PLA2G5 phospholipase A2, group V -3.30 0.002 -2.15 0.019
1554485_s_at TMEM37 transmembrane protein 37 -3.46 0.001 -1.88 0.023
240873_x_at DAB2 Dab, mitogen-responsive phosphoprotein, homolog 2
(Drosophila)
-2.79 0.029 -2.40 0.005
1555729_a_at CD209 CD209 molecule -2.51 0.009 -2.27 0.028
203414_at MMD monocyte to macrophage differentiation-associated -2.64 0.036 -2.07 0.045
213001_at ANGPTL2 angiopoietin-like 2 -2.60 0.013 -2.02 0.041
232712_at — — -2.70 0.044 -1.82 0.031
209543_s_at CD34 CD34 molecule -2.31 0.043 -2.11 0.049
228347_at SIX1 SIX homeobox 1 -2.37 0.036 -2.00 0.034
206856_at LILRB5 leukocyte immunoglobulin-like receptor, subfamily B (with
TM and ITIM domains), member 5
-2.74 0.008 -1.61 0.030
231846_at FOXRED2 FAD-dependent oxidoreductase domain containing 2 -2.23 0.039 -2.10 0.012
226841_at MPEG1 macrophage expressed 1 -2.26 0.031 -2.05 0.020
206178_at PLA2G5 phospholipase A2, group V -2.27 0.003 -1.82 0.024
206726_at HPGDS hematopoietic prostaglandin D synthase -2.17 0.006 -1.89 0.008
244111_at KRT222 keratin 222 -2.39 0.023 -1.65 0.043
238151_at — — -2.21 0.003 -1.74 0.029
204829_s_at FOLR2 folate receptor 2 (fetal) -2.25 0.003 -1.57 0.040
222876_s_at ADAP2 ArfGAP with dual PH domains 2 -2.10 0.012 -1.69 0.035
225228_at DRAM2 DNA-damage regulated autophagy modulator 2 -1.88 0.048 -1.60 0.031
218032_at SNN stannin -1.68 0.020 -1.51 0.024
218633_x_at ABHD10 abhydrolase domain containing 10 -1.53 0.031 -1.50 0.048
doi:10.1371/journal.pone.0137654.t002
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known history of orbital disease. The grouping clearly shows that TED is much more similar to
control tissue compared to subjects with sarcoidosis, most subjects with NSOI, or patients with
GPA.
Another way to represent the correspondence of complex data sets is to display the results
as an unsupervised cluster dendrogram in which the height of the branches reflects the relative
difference between the branches. The dendrograms at the top of Figs 3 and 4 are based on the
validation set and indicate that subjects with TED display gene expression patterns that cluster
with patterns for uninflamed controls in the branches labeled C and D. In contrast, the patterns
for subjects with sarcoidosis or GPA are found in the A and B branches. The NSOI subject pat-
terns are distributed more widely, but only a minority is in the C and D branches. Dendro-
grams for a similar analysis of the discovery set data are shown in S1 and S2 Figs. The
dendrograms indicate that the TED expression pattern is more closely aligned to healthy tissue
than to diseased tissue from patients with sarcoidosis, GPA, or NSOI.
The heat maps below the dendrograms indicate the relative expression of some immunolog-
ically important transcripts: immunoglobulins, cytokines, and cytokine receptors in Fig 3 and
chemokine and chemokine receptors in Fig 4. The heat map columns are aligned with the cor-
responding samples in the dendrogram. Heat maps for a similar analysis of the discovery set
data are shown in S1 and S2 Figs. These figures indicate clearly that diseases such as GPA, sar-
coidosis, and NSOI are much more associated with increased expression of these transcripts in
comparison to TED.
We considered a variety of potential confounders for this study including whether the
biopsy was obtained prior to therapy or subsequent to therapy and whether the patient was on
corticosteroids at the time of biopsy. Surprisingly neither of these variables appears to be con-
tributing to the results.
Discussion
A recent review from respected authorities on TED concluded: “lymphocytes and cytokines are
intimately involved in the initiation, amplification, and maintenance of the autoimmune pro-
cess in TED.” [21] TED is widely considered to be an immune-mediated disease. Observations
that support this include its improvement with prednisone or B cell depleting therapy [22], its
co-existence with Graves’ disease which is driven by autoantibodies, and increased expression
of cytokines in the affected orbital tissue [14, 23, 24]. However, a randomized controlled trial
using B cell depletion failed to demonstrate benefit for TED [25]. The therapeutic effect of
prednisone is nonspecific since corticosteroids regulate many genes in addition to those
Fig 2. Principal component analysis reveals that gene expression in TED orbital adipose is more
similar to uninflamed controls than to tissues from subjects with sarcoidosis, GPA, or NSOI.
C = control. T = TED. N = NSOI. S = Sarcoidosis. G = GPA. Set 1 is based on the discovery set and Set2 is
based on the validation set.
doi:10.1371/journal.pone.0137654.g002
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Fig 3. A dendrogram produced by hierarchical cluster analysis and an independently created heat
map of signals for immunoglobulin, cytokine, and cytokine receptor transcripts compares the
expression profiles of subjects within each disease group in array dataset 2. The heat maps were
created with the GSEA program comparing probe set signal levels for subjects in branches A and B versus
branches C and D. Genes with the highest signals in branches A and B are at the top of each section. The
end branch labels are N—NSOI, S—sarcoidosis, G—GPA, T—TED, C—control.
doi:10.1371/journal.pone.0137654.g003
Immune Response in Thyroid Eye Disease
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involved in immune responses [26]. In parallel with our investigation of TED, we have col-
lected tissue from patients with additional forms of orbital inflammation including sarcoidosis,
GPA, and NSOI. Juxtaposing gene expression from TED with gene expression from 3 other
causes of exophthalmos shows that inflammatory markers are much less commonly associated
with TED relative to the other two diagnoses.
Fig 4. Heat map showing relative chemokine and chemokine receptor expression aligned with the
same dendrogram shown in Fig 3.
doi:10.1371/journal.pone.0137654.g004
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We recently reported on the immunohistochemical detection of IgG4 in biopsies from
patients with either orbital or lacrimal disease [27]. IgG4 is widely accepted as a marker of
immune activation [28]. We detected IgG4 in 30% or more of subjects with GPA, sarcoidosis,
or NSOI. However, substantial IgG4 staining was consistently absent in tissue from subjects
with TED or healthy controls. These observations further support the contention that only a
low level of inflammation generally accompanies thyroid eye disease. Our studies do not mean
that the immune response has no role in the pathogenesis of TED. However, its role is relatively
slight, suggesting that metabolic or other pathways might be better therapeutic targets to treat
TED.
Several previous groups have attempted to clarify the pathogenesis of TED using broad
amplification techniques similar to what we describe [11–15]. Our approach has advantages
over prior studies. It is the first to be able to make comparisons to tissue representing other
forms of orbital inflammation. It is the first to include both a discovery and a validation set.
We have previously validated our microarray data using quantitative PCR and have shown a
correlation of greater than 0.7 between the PCR and microarray values.
We also acknowledge limitations. While the diagnosis of TED is rarely controversial, we
have relied on the clinical expertise from multiple centers such that we cannot exclude some
diagnostic heterogeneity. Our gene expression data, however, support that we have studied a
fairly uniform disease entity. As stated in the methods, about 60% of the patients with TED
in this study were biopsied prior to starting therapy. Most of the biopsies were performed
one or more years after disease onset. It is possible, therefore, that many of the biopsies were
obtained after an early phase of TED that may have a more active, immune-mediated com-
ponent. It is also possible that biopsy of extra-ocular muscle would have revealed an inflam-
matory signature that we could not detect in adipose tissue. Relief of symptoms was the
motivation for most of the TED biopsies, whereas biopsies of the other diseases were pri-
marily for diagnostic purposes. This difference might lead to the other diseases being sam-
pled during an earlier, stage of disease, although in prior published analysis of gene
expression in orbital inflammatory disease we could not demonstrate that disease duration
affected levels of transcripts [29]. Our sample numbers were too small to test for differences
due to demographic variables, such as age and gender, so to compare the disease groups we
used linear models after controlling for these variables. We are in the process of collecting
additional biopsies to assess the role of disease duration, therapy, and site of biopsy more
thoroughly. We also acknowledge that artifacts can result from multiple statistical
comparisons.
Some patients with thyroid eye disease are euthyroid. Others develop orbital disease well in
advance of clinical thyroid disease. We believe that this approach to gene expression profiling
will complement any information that can be gleaned by light microscopy such that ultimately
orbital disease will be diagnosed in part by gene expression profiling.
An analysis of the molecular pattern of gene expression in TED also has the potential to
clarify pathogenesis and thus to suggest new forms of therapy. Furthermore, some patients
with TED have disease which is especially protracted. We predict that gene expression will help
to identify subsets of patients such as those whose disease is especially aggressive or persistent
or those who are especially likely to benefit from specific forms of therapy. Our observations
support an approach to therapy that is not based solely on immunosuppression.
Supporting Information
S1 Fig. A dendrogram produced by hierarchical cluster analysis and an independently cre-
ated heat map of signals for cytokine and cytokine receptor transcripts compares the
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expression profiles of subjects within each disease group in array dataset 1. The end branch
labels are N—NSOI, S—sarcoidosis, G—GPA, T—TED, C—control.
(PDF)
S2 Fig. A dendrogram produced by hierarchical cluster analysis and an independently cre-
ated heat map of signals for chemokine and chemokine receptor transcripts compares the
expression profiles of subjects within each disease group in array dataset 1. The end branch
labels are N—NSOI, S—sarcoidosis, G—GPA, T—TED, C—control.
(PDF)
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